A decision tree for rapid quality assurance and control of rifampicin-containing oral dosage forms for global distribution for tuberculosis treatment.
For centuries tuberculosis remained as a complex socioeconomic problem impeding human development. Directly observed treatment short-course and fixed dose combinations were implemented in tuberculosis therapy for maximum success of treatment. However, drug shortages primarily hindered the expansion of directly observed treatment short-course, which lead to development of the global tuberculosis drug facility. Since large geographical area is covered by the global tuberculosis drug facility for global drug supply for tuberculosis eradication programs, a rapid quality control and assurance has become necessary to ensure the quality and performance of supplied antituberculosis drugs. In this manuscript a decision tree is proposed for facilitating rapid quality control (in vitro and in vivo) of antituberculosis formulations procured by the global tuberculosis drug facility. This decision tree also predicted to be applicable at every stages of anti tuberculosis drug product development, especially in identification of poor quality products and monitoring batch-to-batch variability. Further, it provides opportunity for effective quality control in resource poor settings and the gained knowledge is anticipated to be applicable for development and evaluation of antimalarial and antiAIDS fixed dose combinations.
Ashokraj
Y
Y
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar, Punjab - 160 062, India.
Agrawal
Shrutidevi
S
Panchagnula
R
R
Int J Tuberc Lung Dis. 2005 Jun;9(6):697-9
15971401
Int J Tuberc Lung Dis. 2002 Apr;6(4):356-61
11936746
Int J Tuberc Lung Dis. 2005 Jul;9(7):791-6
16013776
Int J Tuberc Lung Dis. 2005 Jan;9(1):75-80
15675554
Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):703-21
15632956
Int J Tuberc Lung Dis. 2004 Sep;8(9):1081-8
15455592
Int J Tuberc Lung Dis. 2004 Jan;8(1):130-8
14974756
Int J Pharm. 2004 Mar 1;271(1-2):1-4
15129967